Axogen, Inc. Reports Second Quarter 2025 Financial Results

Core Insights - Axogen, Inc. has raised its full-year revenue guidance to at least 17% growth, equating to approximately $219 million [5] - The company reported strong second-quarter results, with revenue of $56.7 million, an 18.3% increase compared to the same quarter in 2024 [6][7] - The CEO expressed confidence in the company's strategic plan and market development objectives, emphasizing the goal of making peripheral nerve function restoration a standard of care [3] Financial Performance - Second-quarter revenue was $56.7 million, reflecting an 18.3% increase year-over-year and a 16.7% increase from the first quarter of 2025 [6][7] - Gross margin for the second quarter was 74.2%, up from 73.8% in the same quarter of 2024 [6] - Net income for the quarter was $0.6 million, or $0.01 per share, compared to a net loss of $1.9 million, or $0.04 per share, in the second quarter of 2024 [6][7] - Adjusted net income for the quarter was $5.7 million, or $0.12 per share, compared to $2.0 million, or $0.05 per share, for the same period in 2024 [6][7] Business Highlights - The company achieved broad-based revenue growth across all markets, including Extremities, Oral Maxillofacial & Head and Neck, and Breast [7] - Coverage and reimbursement for nerve repair using synthetic conduits or allografts expanded by an estimated 10 million new covered lives in 2025, totaling approximately 17 million new lives covered [7] - The FDA accepted the filing of the Biologics License Application for Avance® Nerve Graft, with a goal date for approval set for September 5, 2025 [7] Cash Position - As of June 30, 2025, the balance of cash and cash equivalents, restricted cash, and investments was $35.9 million, down from $39.5 million at the end of 2024 [6] - The company expects to be net cash flow positive for the full year [5]